Abstract
Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0%; P=0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0%; P=0.001), and mean liver iron concentration from 24.2±9.0 to 17.6± 12.9 mg Fe/g dry weight (-27.1%; P=0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of
| Original language | English |
|---|---|
| Pages (from-to) | 405-409 |
| Number of pages | 5 |
| Journal | Annals of Hematology |
| Volume | 89 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2010 |
Fingerprint
Keywords
- β-thalassemia
- Iron chelation
- Iron overload
- Magnetic resonance imaging
- Myocardial iron
- T2*
ASJC Scopus subject areas
- Hematology
Cite this
Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major. / Pathare, Anil; Taher, Ali; Daar, Shahina.
In: Annals of Hematology, Vol. 89, No. 4, 04.2010, p. 405-409.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
AU - Pathare, Anil
AU - Taher, Ali
AU - Daar, Shahina
PY - 2010/4
Y1 - 2010/4
N2 - Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0%; P=0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0%; P=0.001), and mean liver iron concentration from 24.2±9.0 to 17.6± 12.9 mg Fe/g dry weight (-27.1%; P=0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of
AB - Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0%; P=0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0%; P=0.001), and mean liver iron concentration from 24.2±9.0 to 17.6± 12.9 mg Fe/g dry weight (-27.1%; P=0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of
KW - β-thalassemia
KW - Iron chelation
KW - Iron overload
KW - Magnetic resonance imaging
KW - Myocardial iron
KW - T2
UR - http://www.scopus.com/inward/record.url?scp=77649296214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77649296214&partnerID=8YFLogxK
U2 - 10.1007/s00277-009-0838-z
DO - 10.1007/s00277-009-0838-z
M3 - Article
C2 - 19798501
AN - SCOPUS:77649296214
VL - 89
SP - 405
EP - 409
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 4
ER -